Seven Fleet Capital Management LP Has $18.54 Million Position in Enliven Therapeutics, Inc. $ELVN

Seven Fleet Capital Management LP grew its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 40.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 365,386 shares of the company’s stock after purchasing an additional 106,103 shares during the period. Enliven Therapeutics accounts for 3.1% of Seven Fleet Capital Management LP’s portfolio, making the stock its 6th biggest position. Seven Fleet Capital Management LP’s holdings in Enliven Therapeutics were worth $18,543,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Enliven Therapeutics by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after buying an additional 1,693 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after acquiring an additional 80,506 shares during the period. Jane Street Group LLC bought a new position in Enliven Therapeutics in the first quarter worth about $578,000. Legal & General Group Plc boosted its stake in Enliven Therapeutics by 52.2% in the second quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock valued at $646,000 after acquiring an additional 11,058 shares during the period. Finally, Quantbot Technologies LP boosted its stake in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on ELVN shares. Mizuho increased their price target on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. HC Wainwright upped their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Finally, Guggenheim cut their target price on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $75.00.

Insider Buying and Selling

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the sale, the chief financial officer directly owned 40,036 shares in the company, valued at approximately $2,345,308.88. The trade was a 13.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika Derynck sold 158,795 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the completion of the sale, the director directly owned 87,373 shares of the company’s stock, valued at $5,260,728.33. The trade was a 64.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 186,849 shares of company stock valued at $10,998,857 over the last three months. Company insiders own 3.00% of the company’s stock.

Enliven Therapeutics Price Performance

NASDAQ ELVN opened at $59.32 on Friday. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32. The firm has a market capitalization of $4.35 billion, a PE ratio of -35.52 and a beta of 0.30. The company’s 50 day simple moving average is $55.66 and its 200 day simple moving average is $44.19.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.